Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
VOYDEYA (DANICOPAN) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
VOYDEYA
NDA
Get alerts
DANICOPAN | N218037 | ALEXION PHARMACEUTICALS INC
2 strengths
2 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
2 unique patents, 2 exclusivities by expiration date
All strengths
50MG
100MG
Active (2)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
Today
9796741
Feb. 25, 2035
12076319
Aug. 2, 2038
NCE
Mar. 29, 2029
ODE-476
Mar. 29, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 50MG
RLD
2 patents
2 exclusivities
▴
TABLET;ORAL | Approved: Mar 29, 2024
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9796741
Feb 25, 2035
—
Yes
—
U-3933
TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB
—
12076319
Aug 2, 2038
—
—
—
U-3933
TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB
—
Exclusivities (2)
Code
Date
Status
NCE
Mar 29, 2029
Active
ODE-476
Mar 29, 2031
Active
#002 — 100MG
RLD
2 patents
2 exclusivities
▾
TABLET;ORAL | Approved: Mar 29, 2024